Calidi Biotherapeutics reported a net loss of $11.9 million for the nine months ended September 30, 2026, compared to a $16.0 million loss in the prior year period. The company maintained a cash balance of $3.9 million as of September 30, 2026, and completed a 1-for-16 reverse stock split in July 2026 to adjust its capital structure.
Calidi Biotherapeutics reported a net loss of $3.6 million for the third quarter of 2026, a significant improvement from the $10.8 million loss in the prior year period. The company highlighted preclinical progress for its CLD-401 program and implemented a restructuring plan on November 6, 2026, to reduce headcount and save $3 million annually. During the quarter, the company also raised $1.2 million through an at-the-market offering to extend its cash runway.
Term
Q3 2026
“Throughout the third quarter, Calidi continued to advance its RedTail platform for systemic and local delivery and redefine the potential of oncolytic viruses and genetic medicine. In particular, CLD-401 demonstrated remarkable anti-tumor activity with systemic administration in syngeneic tumor models and continues to progress towards the clinic.”
Calidi Biotherapeutics received a deficiency notice from NYSE American for failing to maintain the minimum stockholders' equity requirement of $4.0 million. The company reported stockholders' equity of $3.1 million as of June 30, 2026, and has until October 21, 2026, to submit a plan to regain compliance by March 21, 2028.
Calidi Biotherapeutics entered into a stock purchase agreement to sell 1,025,640 shares of common stock in a registered direct offering at $1.17 per share. The offering generated gross proceeds of approximately $1.2 million, which the company intends to use for working capital and general corporate purposes.